

This is an Accepted Manuscript of an article published by Elsevier in Industrial Crops and Products on 22 May 2019, available at: <https://doi.org/10.1016/j.indcrop.2019.05.069>.

This manuscript version is made available under the CC-BY-NC-ND 4.0 license <https://creativecommons.org/licenses/by-nc-nd/4.0>"

1

2

3 **Sardinian plants with antimicrobial potential. Biological screening with multivariate data**  
4 **treatment of thirty-six extracts**

5

6 Mandrone M.<sup>a</sup>, Bonvicini F.<sup>b,\*</sup>, Lianza, M.<sup>a</sup>, Sanna C.<sup>c</sup>, Maxia A.<sup>c</sup>, Gentilomi G.A.<sup>b,d</sup>, Poli F.<sup>a</sup>

7

8

9 <sup>a</sup>Department of Pharmacy and Biotechnology, University of Bologna, Via Irnerio 42, 40126

10 Bologna, Italy

11

12 <sup>b</sup>Department of Pharmacy and Biotechnology, University of Bologna, Via Massarenti 9, 40138

13 Bologna, Italy

14

15 <sup>c</sup>Department of Life and Environmental Sciences, University of Cagliari, Via Sant' Ignazio da

16 Laconi 13, 09123, Cagliari, Italy

17

18 <sup>d</sup>Unit of Microbiology, S. Orsola-Malpighi Hospital-University of Bologna, Via Massarenti 9, 40138

19 Bologna, Italy.

20

21

22 **\*Correspondence**

23 Dr. Francesca Bonvicini, Department of Pharmacy and Biotechnology, University of Bologna, Via

24 Massarenti 9, 40138 Bologna, Italy

25 E-mail: francesca.bonvicini4@unibo.it

26

27

28 **Abstract**

29 In this paper, thirty-six extracts from Sardinian plants were evaluated *in vitro* for their antimicrobial  
30 activity towards a panel of reference strains, *Staphylococcus aureus*, *S. epidermidis*, *Klebsiella*  
31 *pneumoniae* and *Escherichia coli*, and for their cytotoxicity on mammalian cells. The biological data,  
32 together with total phenolic and flavonoid content of the extracts, were treated by PCA, which  
33 highlighted the positive correlation among total phenolic content and increasing antibacterial  
34 activities, and a possible involvement of flavonoids in mitigate the cytotoxicity. Thirteen extracts  
35 displayed a significant inhibitory effect towards *S. aureus* (IC<sub>50</sub> from 1.4 to 153.6 µg/mL), ten out of  
36 them were active also against *S. epidermidis* (IC<sub>50</sub> from 3.9 to 150 µg/mL), seven against *K.*  
37 *pneumoniae* (IC<sub>50</sub> from 28.5 to 97.5 µg/mL), and two against *E. coli* (IC<sub>50</sub> 74.9 and 156.3 µg/mL). In  
38 particular, three extracts obtained from *Pistacia terebinthus ssp. terebinthus*, *Cytinus hypocistis* and  
39 *Limonium morisianum* emerged as promising antibacterial candidates. They exhibited remarkable  
40 inhibitory activity towards bacterial strains from clinical specimens and presenting different  
41 antibiotic-resistance profiles.

42

43

44 **Keywords**

45 Antimicrobials; Sardinian plants; *Pistacia terebinthus ssp. terebinthus*; *Cytinus hypocistis*;

46 *Limonium morisianum*; multivariate data treatment.

47

48

49

50

51

52

53 **1. Introduction**

54 In the current scenario, the clinical use of antibiotics, and therefore the effective treatment of bacterial  
55 infections, is under considerable threat due to the emergence of bacteria that have developed  
56 resistance to many classes of generally used antibiotics. Antibiotic-resistant bacterial infections are  
57 already widespread across the globe and very high rates of resistance have been ever-increasingly  
58 observed in common bacteria (WHO, 2014). Among *Staphylococcus* species, the prevalence of  
59 methicillin-resistant *S. aureus* and *S. epidermidis* (MRSA and MRSE, respectively) infections is  
60 growing worldwide and epidemiology is changing overtime. Although *S. aureus* and *S. epidermidis*  
61 are normal commensals of the skin and mucous membranes, MRSA is a leading cause of nosocomial  
62 infections and, more and more frequently, it is associated to community-acquired infections (mainly  
63 skin and wound infections) while MRSE has been identified as the most recurrent cause of health-  
64 care related bloodstream and device-related infections (Moellering, 2012; Rolo et al., 2012; May et  
65 al., 2014). Concerning Gram negative bacteria, high proportions of resistance to cephalosporins and  
66 fluoroquinolones have been reported for *Escherichia coli*, a normal inhabitants of the human  
67 intestinal microflora, and, of great concern, to carbapenems for *Klebsiella pneumoniae*, a primarily  
68 opportunistic bacterium that can be nosocomial or community acquired. These high reported  
69 resistances mean limitations to available treatment, which may be common in the population, such as  
70 urinary tract infections and pneumonia (Nordman et al., 2011).

71 Generally, infections by drug-resistant bacteria have an increased risk of worse clinical outcome and  
72 death compared to infections by the respective susceptible strains, and treatments must rely on  
73 second-line drugs that are more expensive and, sometimes, they have severe side-effects for which  
74 monitoring is advisable, increasing costs even further.

75 All these remarks have hastened and widened the quest for the discovery of novel agents for the  
76 treatment of bacterial infections.

77 In this context, plants represent a very important resource, producing hundreds of diverse metabolites,  
78 with medicinal and nutraceutical potential (Cragg & Newman 2013, Toledo et al., 2015; Chen et al.,

79 2014; Fung et al. 2013). Among their bioactivities, plant metabolites were proved also endowed with  
80 antimicrobial potential (Coqueiro et al., 2016; Snene et al., 2017; Dikpınar et al., 2018; Mahadi et al.,  
81 2018). In addition to find new antimicrobial molecules, plant extracts resulted interesting to study  
82 also for their non-antimicrobial compounds, which might be essential for the total bioactivity of the  
83 extract, improving solubility, absorption and stability of the active metabolites. Moreover, some  
84 phytochemicals, despite not being antimicrobial by themselves, showed antibiotic adjuvant activity,  
85 due to the inhibition of pathogens resistance mechanisms (Abreu et al., 2016, Abreu et al., 2017).

86 Sardinia (Italy), due to its geographical isolation and high geological and geomorphological  
87 diversification, represents a hotspot for biodiversity within the Mediterranean basin (Médail &  
88 Quézel, 1997; Médail & Quézel, 1999; Marignani et al., 2017). This Island constitutes an extremely  
89 diverse and dynamic environment with wide range of habitats and high degree of endemism (Fois et  
90 al., 2017), driving plants to increase and diversify the production of their secondary metabolites in  
91 order to adapt, compete and communicate with other species (Jahangir et al., 2008; Wang et al., 2005).

92 In fact, Sardinian plants were found generally endowed with peculiar features, both in respect of the  
93 phytochemical and genetic profiles (Bobo-Pinilla et al., 2016; Dettori et al., 2016; Marengo et al.,  
94 2017; Sanna et al., 2018a; Venditti et al., 2017; Venditti et al. 2018).

95 However, despite Sardinian endemic plants resulted interesting for their phytochemical and biological  
96 features, yielding also new molecular scaffolds (Cagno et al., 2017; Daino et al., 2018; Mandrone et  
97 al., 2015; Mandrone et al., 2017; Maxia et al., 2015; Ornano et al., 2016; Sanna et al., 2018b; Venditti  
98 et al., 2016), the majority of them remains still poorly investigated.

99 On this basis, thirty-six extracts obtained from Sardinian plants, including twelve endemic species,  
100 were evaluated *in vitro* for their antibacterial activity against Gram positive and Gram negative  
101 reference bacteria, and selected extracts were assayed on a panel of fifteen clinical isolates presenting  
102 different antibiotic-resistance profiles. Moreover, cytotoxicity on mammalian epithelial cells was also  
103 tested.

104 The overall biological data, together with phenolic and flavonoid content, were summarized by  
 105 principal component analysis (PCA).

## 106 2. Methods and materials

### 107 2.1. Plant material

108 **Wild plants** were harvested in Sardinia Island (Italy) during 2017 and 2018 and were identified by  
 109 Dr. Cinzia Sanna and Prof. Andrea Maxia. Vouchers were deposited at the General Herbarium of the  
 110 Department of Life and Environmental Sciences, University of Cagliari and reported in Table 1,  
 111 where plants were listed in alphabetical order using the update nomenclature reported in the new  
 112 checklist of Italian vascular flora (Bartolucci et al., 2018).

113

114 **Table 1** The table lists all the plants used in this study. The update botanical names, the plant organ  
 115 used and their labels, families, places and dates of collection and voucher numbers were reported.

116

Plant name	Plant organ and sample label in brackets	Family	Location of harvesting	Harvesting date	Voucher
<i>Arbutus unedo</i> L.	Fruits (AuF)	Ericaceae	Jerzu	December 2017	Herbarium CAG 878
	Leaves (AuL)		Jerzu	December 2017	
<i>Asphodelus ramosus</i> L. subsp <i>ramosus</i>	Rhizome (ArRh)	Asphodelaceae	Geremeas	April 2017	Herbarium CA 1405
	Leaves (ArL)		Geremeas	April 2017	
<i>Carlina gummifera</i> (L.) Less.	Leaves (CgL)	Asteraceae	Cala Surya (Cardedu)	July 2018	Herbarium CAG 770
<i>Centaurea calcitrapa</i> L.	Aerial parts (CcA)	Asteraceae	Siliqua	June 2017	Herbarium CAG 781
<i>Centaurea horrida</i> Badarò*	Aerial parts (ChA)	Asteraceae	Capo Falcone	June 2017	Herbarium CAG 777
<i>Centaurea napifolia</i> L.	Aerial parts (CnA)	Asteraceae	Uta	June 2017	Herbarium CAG 784
<i>Cistus monspeliensis</i> L.	Aerial parts (CmA)	Cistaceae	Cala Surya (Cardedu)	April 2018	Herbarium CAG 135

ha formattato: Francese (Francia)

<i>Cistus salvifolius</i> L.	Aerial parts (CsA)	Cistaceae	Cala Surya (Cardedu)	April 2018	Herbarium CAG 135/C
<i>Cynara cardunculus</i> L.	Aerial parts (CycA)	Asteraceae	Siliqua	April 2017	Herbarium CAG 790
<i>Cytinus hypocistis</i> (L.) L.	Aerial parts (CyhA)	Cytinaceae	Gesturi	May 2017	Herbarium CAG 1200
<i>Ferula arrigonii</i> Bocchieri*	Leaves (FaL)	Apiaceae	Tharros	April 2017	Herbarium CAG 612/A
	Roots (FaR)		Tharros	April 2017	
<i>Galactites tomentosa</i> Moench	Aerial parts (GtA)	Asteraceae	Jerzu	September 2018	Herbarium CAG 789
<i>Genista corsica</i> (Loisel.) DC*	Aerial parts (GcA)	Fabaceae	Seui	May 2017	Herbarium CAG 286
<i>Glechoma sardoa</i> (Bég.) Bég.*	Aerial parts (GsA)	Lamiaceae	Gennargentu	June 2017	Herbarium CAG 1104
<i>Hypericum hircinum</i> L. ssp. <i>hircinum</i> *	Aerial parts (HhA)	Hypericaceae	Jerzu	June 2018	Herbarium CAG 232
<i>Hypericum scruglii</i> Bacch., Brullo & Salmeri*	Aerial parts (HsA)	Hypericaceae	Jerzu	June 2018	Herbarium CAG 239/C
<i>Lavandula stoechas</i> L.	Aerial parts (LsA)	Lamiaceae	Cala Surya (Cardedu)	April 2017	Herbarium CAG 1067
<i>Limonium morisianum</i> Arrigoni*	Aerial parts (LmA)	Plumbaginaceae	Jerzu	December 2017	Herbarium CAG 909/G
<i>Myrtus communis</i> L.	Fruits (McF)	Myrtaceae	Cala Surya (Cardedu)	December 2018	Herbarium CAG 514
	Leaves (McL)		Poggio dei Pini	April 2018	
<i>Pistacia lentiscus</i> L.	Fruits (PIF)	Anacardiaceae	Cala Surya (Cardedu)	December 2017	Herbarium CAG 280
	Leaves (PIL)		Cala Surya (Cardedu)	December 2017	
<i>Pistacia terebinthus</i> L. ssp. <i>terebinthus</i>	Leaves (PtL)	Anacardiaceae	Jerzu	June 2018	Herbarium CAG 279
<i>Plagiopus flosculosus</i> (L.) Alavi & Heywood*	Aerial parts (PfA)	Asteraceae	Iglesias	July 2017	Herbarium CAG 743
<i>Ptilostemon casabonae</i> (L.) Greuter*	Aerial parts (PcA)	Asteraceae	Gairo Taqisara	June 2018	Herbarium CAG 796
<i>Rosmarinus officinalis</i> L.	Aerial parts (RoA)	Lamiaceae	Alghero	May 2017	Herbarium CAG 1091
<i>Santolina corsica</i> Jord. & Fourr*	Aerial parts (ScA)	Asteraceae	Monte Albo	November 2017	Herbarium CAG 732/A
<i>Scolymus hispanicus</i> L. subsp. <i>hispanicus</i>	Aerial parts (ShA)	Asteraceae	Sarroch	June 2018	Herbarium CAG 812



<i>Silybum marianum</i> (L.) Gaertn.	Aerial parts (SmA)	Asteraceae	Uta	May 2017	Herbarium CAG 801
<i>Smilax aspera</i> L.	Aerial parts (SaA)	Smilacaceae	Geremeas	May 2017	Herbarium CAG 1414
<i>Stachys glutinosa</i> L.*	Aerial parts (SgA)	Lamiaceae	Gennargentu	June 2017	Herbarium CAG 1099
<i>Tanacetum audibertii</i> (Req.) DC*	Aerial parts (TaA)	Asteraceae	Gennargentu	August 2018	Herbarium CAG 737/A
<i>Thymus herba barona</i> Loisel.	Aerial parts (ThA)	Lamiaceae	Gennargentu	June 2017	Herbarium CAG 1065

117 \*Endemic species of Sardinia

118

## 119 2.2. Chemicals and extracts preparation

120 All solvents and reagents were purchased from Sigma-Aldrich (Milan, Italy), MeOH was an  
121 analytical grade ( $\geq 99.9\%$ ).

122 Thirty mg of dried and powdered plant material were extracted by sonication for 30 minutes using  
123 1.5 mL of MeOH/H<sub>2</sub>O (1:1). Subsequently, samples were centrifuged ( $1700 \times g$ ) for 20 min, the  
124 supernatant was separated from the pellet and dried, firstly in vacuum concentrators (speedVac SPD  
125 101b 230, Savant, Italy) for two hours to remove MeOH, then the residual extracts were freeze-dried  
126 over night to completely remove the residual H<sub>2</sub>O finally yielding the crude extracts. For each sample  
127 different extracts were produced, in an adequate number to perform all the biological tests in  
128 replicates. This extraction procedure is designed to be performed relatively quickly and to prepare  
129 little quantity of extracts for *in vitro* bioactivity tests, been ideal for screenings of high number of  
130 plants. Moreover, this procedure allows a minimal waste of both solvents and plant material. The  
131 choice of a mid-polar solvent system such as aqueous MeOH and the use of sonication are  
132 recommended and used by several metabolomics studies (Kim & Verpoorte, 2010; Verpoorte, R. et  
133 al., 2007), where MeOH/H<sub>2</sub>O (1:1) turned out as the best choice for a first line extraction procedure  
134 for general plant material, since it allows to extract a broad spectrum of compounds. This protocol  
135 has been also used to compare biological activities of plants to their phytochemical profile (Mandrone

136 et al, 2018), resulting also suitable to facilitate further metabolomic studies to identify the active  
137 principles of the extracts.

138 For biological assays, stock solutions were prepared solubilizing extracts in water at 10 mg/mL,  
139 centrifuged to remove the pellet if present, and stored at 4°C until use.

### 140 *2.3. Total flavonoid and phenolic assays*

141 The assays were performed in Spectrophotometer Jasco V-530 as described by Chiocchio et al.  
142 (2018). Briefly, for total phenolic content analysis a calibration curve was constructed using 50 µL  
143 of different gallic acid stock solutions prepared in MeOH 80% (from 10 to 200 µg/mL) mixed with  
144 250 µL of Folin-Ciocalteu reagent (diluted 1:10) and 500 µL of H<sub>2</sub>O. Different stock solutions of  
145 extracts were prepared in water (from 0.05 to 0.2 mg/mL) and 50 µL of each stock were mixed with  
146 the same reagents as described above. Both calibration curve and samples were incubated at room  
147 temperature for 5 min before adding 800 µL of sodium carbonate solution (Na<sub>2</sub>CO<sub>3</sub> 20%). After 30  
148 min of incubation at 40°C, absorption was recorded at 760 nm. Total phenolic content was calculated  
149 by interpolation in the calibration curve and expressed as: mg GAE (gallic acid equivalent)/g of  
150 extract (dried weight).

151 Total flavonoid content was determined using rutin to perform the calibration curve. Different stock  
152 solutions of extracts were prepared in water (from 0.05 to 0.2 mg/mL) and 50 µL of each one were  
153 mixed with 450 µL of methanol and 500 µL of AlCl<sub>3</sub> (2% w/volume of methanol). The absorption at  
154 430 nm was recorded after incubation (15 min) at room temperature. The calibration curve was  
155 obtained using 50 µL of different rutin stock solutions prepared in DMSO (from 1 to 100 µg/mL).  
156 Total flavonoid content of the extracts was calculated by interpolation in the calibration curve and  
157 expressed in terms of mg RE (rutin equivalent)/g of extract (dried weight). Analysis were performed  
158 in triplicate.

### 159 *2.4. Multivariate data analysis*

160 For multivariate analyses (PCA), data were subjected to UV (United Variance) scaling and the model  
161 was developed using SIMCA P+ software (v. 15.0, Umetrics, Sweden).

162 2.5. Bacterial *reference* strains and clinical isolates

163 *Staphylococcus aureus* ATCC 25293, *Staphylococcus epidermidis* (ATCC 12228), *Escherichia coli*  
164 (ATCC 25922) and *Klebsiella pneumoniae* (ATCC 9591) were obtained from the American Type  
165 Culture Collection. Subsequently, having defined the antibacterial properties of the extracts, the main  
166 active were assayed towards 15 clinical isolates recovered from different clinical specimens, and  
167 collected at the Microbiology Unit, St Orsola Malpighi University Hospital, Bologna, Italy. Strains  
168 included 5 *S. aureus* of which 3 methicillin-resistant (MRSA), 5 *S. epidermidis* of which 3  
169 methicillin-resistant (MRSE) and 5 *K. pneumoniae* of which 2 carbapenemase-producing (KPC-  
170 producing *K. pneumoniae*). Species identification and antimicrobial susceptibility testing were  
171 performed by Vitek2 semi-automated system (bioMerieux, France), and EUCAST criteria were used  
172 for the interpretation of results and for the definition of methicillin and carbapenem resistance.

173 2.6. Determination of antibacterial activity

174 The *in vitro* antibacterial activity of the thirty-six extracts was evaluated against **four reference strains**  
175 **and some selected extracts towards** clinical isolates by a broth microdilution method (Bonvicini et  
176 al., 2014; Bonvicini et al., 2017). The bacterial suspension, prepared in Mueller Hinton broth (Sigma-  
177 Aldrich, St. Louis, USA) was incubated with the extracts at 200 µg/mL or serially two-fold diluted  
178 from 200 µg/mL depending on the assay. A number of wells was reserved in each microplate for  
179 negative (no inoculum added) and positive growth controls. The microplate was incubated at 37°C  
180 for 24h, and subsequently the OD<sub>630 nm</sub> was spectrophotometrically measured (**Multiskan Ascent**  
181 **microplate reader, Thermo Fisher Scientific Inc., Waltham, USA**). Growth percentage values were  
182 determined as relative to the positive control. Extracts demonstrating an inhibitory activity superior  
183 to 70% at 200 µg/mL were defined as *active* and their IC<sub>50</sub> values corresponding to the sample  
184 concentrations giving rise to an inhibition of bacterial growth of 50% were obtained by the  
185 interpolation on the dose-response curves. Statistical analysis was carried out by nonlinear regression  
186 method using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego California,  
187 USA). A one-way ANOVA was done for comparison between IC<sub>50</sub> values obtained for **the reference**

188 **strains** and clinical isolates followed by Dunnett's multiple comparison test to detect significant  
189 differences among groups.

### 190 *2.7. Cell viability assay*

191 African green monkey kidney cells (Vero ATCC CCL-81) were cultured in Eagle's Minimal  
192 Essential Medium (MEM) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal  
193 bovine serum (FBS) (Carlo Erba Reagents, Milan, Italy), 100 U/mL penicillin, and 100 µg/mL  
194 streptomycin at 37°C with 5 % CO<sub>2</sub>. For experiments, cells were seeded into 96-well plates at 10<sup>4</sup>  
195 cells/well, and incubated at 37°C for 24h. Cell density and incubation time were previously optimized  
196 (Bonvicini et al., 2018). Following washes with **PBS (phosphate-buffered saline) to remove floating**  
197 **cells**, monolayer was incubated with 100 µL of serially 2-fold dilution of the extract starting from  
198 200 µg/mL, and with standard medium as positive control. The cell viability was assessed by a WST8-  
199 based assay according to the manufacturer's instructions (CCK-8, Cell Counting Kit-8, Dojindo  
200 Molecular Technologies, Rockville, MD, USA). After 48 h of incubation, culture medium was  
201 removed from each well, the monolayer was washed with PBS, and 100 µL of fresh medium  
202 containing 10 µL of CCK-8 solution were added and incubated for 2h at 37°C. Cell viability was  
203 measured at OD<sub>450/630 nm</sub> and expressed as the percentage of the cell viability relative to the untreated  
204 controls. The CC<sub>50</sub> values were obtained by the interpolation of percentage values on the dose-  
205 response curves.

## 206 **3. Results and Discussion**

### 207 *3.1. Screening of biological activities and multivariate data analysis*

208 **The thirty-six extracts were assayed *in vitro* at 200 µg/mL to determine their antibacterial activity**  
209 **towards four reference strains and their cytotoxicity on mammalian epithelial cells. Overall data are**  
210 **reported in Tables S1 and S2 in Supplementary Material and Figure 1. Thirteen out of the thirty-six**  
211 **extracts resulted strong inhibitors of one or more bacteria (30% of bacterial growth compared to the**  
212 **extract-free control), as reported in Table 2. In particular, ten extracts inhibited the growth of both *S.***  
213 ***aureus* and *S. epidermidis*, while three, PIF, RoA and SaA, showed activity only towards *S. aureus*.**

214 Regarding the effectiveness on Gram negative bacteria, seven extracts were effective against *K.*  
 215 *pneumoniae*. Only two extracts, **CyhA and PtL** were able to reduce the growth of all bacterial strains  
 216 below the abovementioned threshold of activity (30%), reducing also *E. coli* activity of **34% and**  
 217 **33%**, respectively, which were the lowest values obtained out of the thirty-six extracts tested.

218  
 219 **Table 2.** Bacterial growth of the reference strains treated with **the 13 most active** extracts at 200  
 220  $\mu\text{g/mL}$ . Data are mean values and standard deviation obtained in two independent experiments  
 221 performed in triplicate. Percentage values are relative to the positive control (100% of growth).

Sample lable	<i>S. aureus</i> ATCC 25293	<i>S. epidermidis</i> ATCC 12228	<i>E. coli</i> ATCC 25292	<i>K. pneumoniae</i> ATCC 9591
AuL	16 ± 3	2 ± 3	58 ± 5	29 ± 5
CmA	8 ± 3	5 ± 5	66 ± 6	18 ± 4
CsA	11 ± 6	3 ± 4	47 ± 4	37 ± 10
CyhA	5 ± 4	3 ± 4	34 ± 14	19 ± 1
LmA	9 ± 4	10 ± 5	69 ± 12	44 ± 6
McF	19 ± 5	12 ± 7	69 ± 7	64 ± 6
McL	5 ± 8	4 ± 6	55 ± 8	26 ± 11
PIF	26 ± 9	49 ± 15	77 ± 8	42 ± 3
PIL	9 ± 8	7 ± 13	47 ± 5	24 ± 7
PtL	4 ± 5	3 ± 3	33 ± 6	17 ± 3
RoA	13 ± 6	74 ± 7	97 ± 6	89 ± 2
SaA	30 ± 11	111 ± 15	73 ± 13	76 ± 4
ThA	13 ± 3	21 ± 15	106 ± 10	90 ± 1

ha eliminato: .

ha eliminato: .

223  
 224 The screening pipeline on the thirty-six extracts included the evaluation of their effects on cell  
 225 viability and proliferation in order to discriminate between a specific ability to affect bacterial growth  
 226 or to a general toxic activity on mammalian cells. As depicted in Figure 1, among the thirty-six  
 227 extracts, eight strongly reduced mammalian cells metabolism below the 30% and, among these

230 extracts, six were labeled as *active* through the microbiological investigations, thus requiring further  
231 evaluations to specify their safety profile.

232 To gain comprehensive insights on the biological properties of all tested extracts, principal  
233 component analysis model (PCA) was build, using as set of x variables: the bioactivity data against  
234 the four bacterial strains (expressed as % of inhibition at 200 µg/mL), the cytotoxicity data (expressed  
235 as % of cell *viability* at 200 µg/mL), and total polyphenols and flavonoids content of the extracts,  
236 expressed as mg of gallic acid equivalents (GAE)/g of extract and % of rutin equivalents (RE)/g of  
237 extract, respectively. These latter phytochemical data are reported in Table S3 of Supplementary  
238 Material.

239 As shown by the PCA scatter plot (Figure 2A), antibacterial activity (against all strains) and phenolic  
240 content followed a similar trend. In fact, extracts shifted on the positive side of the component t[1]  
241 (PC1) were generally endowed with high value of both antibacterial activity and phenolic content.

242 Phenolic compounds might be involved in the positive effects observed, since they have been  
243 recognized as bioactive molecules with pronounced antimicrobial activity (Gomes et al., 2018; Scavo  
244 et al., 2019). Conversely, on the negative side of PC1 axis, the extracts showing no activity on bacteria

245 and an extremely low content of phenolic and flavonoid compounds were grouped. On the positive  
246 side of the PC1 and along the negative side of the component t[2] (PC2) were placed the extracts with  
247 the highest cytotoxicity on mammalian cells, such as *CycA* and *CcA*, and showing only a medium  
248 activity against *Staphylococci* spp. High level of cytotoxicity on Vero cells was shown also by *CyhA*,  
249 *AuL* and *CsA*, which followed, in fact, a similar trend along the PC2, shifting toward the lower-right  
250 quadrant of the plot. Nevertheless, their strong antibacterial activities made those extracts still  
251 interesting for further investigations (IC<sub>50</sub> and SI determination), while *CycA* and *CcA* were  
252 considered not interesting, due to their strong cytotoxicity while scant antibacterial activity.

253 On the upper part of the plot (positive PC2), the extracts with medium antibacterial activity while  
254 very low cytotoxicity were clustered. Interestingly, low toxicity on mammalian cells was associated  
255 to high flavonoids content, suggesting a possible cytoprotective role of these compounds, which are

ha formattato: Colore carattere: Rosso

256 also renowned antioxidants (Hosseinzadeh & Nassiri-Asl, 2014). Among the samples endowed with  
257 high content of flavonoids, a peculiar case was represented by PtL, which, in fact, was identified as  
258 an outlier in the PCA model. This extract showed high content of both phenols and flavonoids, high  
259 antibacterial activity against all strains tested and very low cytotoxicity.

260 The herein described model, providing a graphical overview of all biological data, facilitates also  
261 considerations on extracts obtained from plants belonging to the same genus. In particular, samples  
262 included three different species of *Centaurea* genus (*C. calcitrapa*, *C. napifolia* and *C. horrida*), and  
263 two different species of *Pistacia* (*P. lentiscus* and *P. terebinthus* ssp. *terebinthus*), *Cistus* (*C.*  
264 *salvifolius* and *C. monspeliensis*) and *Hypericum* (*H. scruglii* and *H. hircinum* ssp. *hircinum*).  
265 Regarding the three *Centaurea* species (CcA, CnA and ChA), they yielded very similar results,  
266 namely they were proved not active against all pathogens tested and were also poor in phenols and  
267 flavonoids. However, while CnA and ChA were also not cytotoxic on Vero cells, CcA was one of the  
268 highly cytotoxic extract of the dataset. Regarding the two *Cistus* species, CsA and CmA, they were  
269 placed very close in the PCA plot, since they showed a similar trend in both bioactivities and  
270 phenolic/flavonoids content. The same behavior was observed for the two species of *Hypericum* (HsA  
271 and HhA), which resulted both rich in flavonoids, not cytotoxic, while endowed with moderate  
272 antibacterial activity. Finally, the two *Pistacia*, PIL and PtL, were both strongly active against  
273 bacterial strains, even though PtL was more enriched in flavonoids and less cytotoxic than PIL.

274 As shown in Figure 2B, the majority of the samples studied were plant leaves or aerial parts, one was  
275 constituted by rhizomes (ArRh), one by roots (FaR), and three of them were fruits (PIF, McF and  
276 AuF). In case of *Myrtus communis* and *Pistacia lentiscus*, both fruits and leaves extracts were tested  
277 and proved to be active and characterized by similar features, appearing very close into the PCA  
278 scatter plot. Conversely, only leaves of *Arbutus unedo* (AuL) were active, while fruits (AuF), being  
279 not active, were placed on the opposite quadrant of the plot.

280 **3.2. Antibacterial activity and selectivity**

ha eliminato: ing

ha eliminato: in fact,

283 The active subset of the thirteen extracts was further assayed *in vitro* towards some selected bacterial  
 284 strains to obtain IC<sub>50</sub> values on the specific dose-response curves. Based on data in Table 3, some  
 285 general remarks can be drawn. Of the thirteen extracts inhibiting *S. aureus*, five displayed potent one-  
 286 digit µg/mL IC<sub>50</sub> values and CyhA resulted the most effective *S. aureus* inhibitor (IC<sub>50</sub> = 1.4 µg/mL);  
 287 of the ten extracts active towards *S. epidermidis* four exhibited comparable inhibitory effectiveness,  
 288 and LmA displayed the highest activity (IC<sub>50</sub> = 3.9 µg/mL). Concerning Gram negative bacteria,  
 289 according to generally lower inhibition rates, IC<sub>50</sub> values for the active extracts were superior  
 290 compared to those obtained for Gram positive strains, however worthy of note for raw plant extracts  
 291 (Cos et al., 2006). The extracts of CyhA and McL resulted the most potent against *K. pneumoniae*  
 292 (IC<sub>50</sub> = 28.5 µg/mL and IC<sub>50</sub> = 37.0 µg/mL, respectively) and the first one, being active even towards  
 293 *E. coli* (IC<sub>50</sub> = 74.9 µg/mL), displayed a broad spectrum antibacterial activity. Differences in  
 294 susceptibility between Gram positive and Gram negative bacteria are strictly related to the presence  
 295 of the outer membrane and the lipopolysaccharides in the latter cells; these structures form an  
 296 additional barrier that account for the Gram negative increased permeability threshold to many  
 297 molecules.

298  
 299 **Table 3.** Antibacterial activity of the thirteen selected extracts expressed as IC<sub>50</sub> (µg/mL of extract),  
 300 defined as the concentration giving rise to an inhibition of growth of 50% compared to the drug-free  
 301 control. Data are reported as mean values and 95% confidence interval.

302

Sample lable	<i>S. aureus</i>	<i>S. epidermidis</i>	<i>E. coli</i>	<i>K. pneumoniae</i>
	ATCC 25293	ATCC 12228	ATCC 25292	ATCC 9591
AuL	31.9 [26.2-38.8]	10.1 [9.3-10.9]	n.d. <sup>§</sup>	93.8 [81.8-107.6]
CmA	5.3 [4.4-6.5]	12.4 [11.1-13.9]	n.d.	64.65 [57.0-73.2]
CsA	9.0 [7.9-10.4]	29.5 [26.4-32.9]	n.d.	97.5 [80.6-118.1]
CyhA	1.4 [0.9-1.9]	8.0 [7.5-8.5]	74.9 [57.9-96.9]	28.5 [22.8-35.6]
LmA	9.2 [6.8-12.3]	3.9 [2.5-6.1]	n.d.	n.d.



McF	15.4 [10.7-21.9]	8.8 [7.5-10.5]	n.d.	n.d.
McL	7.5 [6.0-9.3]	9.7 [8.9-10.9]	n.d.	37.0 [28.3-48.4]
PIF	144.5 [126.0-165.6]	n.d.	n.d.	n.d.
PIL	27.3 [21.6-34.5]	56.8 [48.1-67.2]	n.d.	48.0 [40.6-56.7]
PtL	62.9[48.6-81.4]	103.1 [92.6-109.0]	156.3[138.1-177.0]	49.0 [42.8-56.0]
RoA	99.2 [83.1-118.5]	n.d.	n.d.	n.d.
SaA	153.6 [129.1-182.7]	n.d.	n.d.	n.d.
ThA	63.3 [55.5-72.1]	150.0 [131.0-171.8]	n.d.	n.d.

<sup>§</sup> n.d. = not determined

304

305 Dose-effect experiments on Vero cells were finally carried out to establish their safety on non-  
306 malignant epithelial cells. Table 4 reports the CC<sub>50</sub> values and the corresponding selectivity index  
307 (SI), calculated as CC<sub>50</sub>/IC<sub>50</sub> ratio, for the bacterial strain more susceptible to inhibition. Samples  
308 obtained from CyhA, LmA and McL presented very high SI in relation to Vero cells on *Staphylococci*  
309 spp. and only moderate values were obtained on *K. pneumoniae*, thus suggesting a preferential  
310 inhibitory activity towards bacterial cells with respect to eukaryotic cells.

311

312 **Table 4.** Cytotoxicity of active extracts against Vero cells and Selectivity Indexes (SI). CC<sub>50</sub> is  
313 defined as the concentration giving rise to an inhibition of cell metabolism of 50% compared to the  
314 drug-free control. Data are reported as mean values and 95% confidence interval. SI = selective index  
315 corresponding to the ratio between CC<sub>50</sub> and IC<sub>50</sub>.

316

Sample lable	CC <sub>50</sub> (µg/mL)	SI
AuL	41.7 [35.0-49.7]	4.1 ( <i>S. epidermidis</i> )
CmA	88.2 [69.6-11.7]	16.5 ( <i>S. aureus</i> )
CsA	53.7 [43.5-66.3]	5.9 ( <i>S. aureus</i> )
CyhA	90.3 [75.2-108.3]	64.7 ( <i>S. aureus</i> ); 3.2 ( <i>K. pneumoniae</i> )
LmA	>200	>51.0 ( <i>S. epidermidis</i> )
McF	>200	>22.6 ( <i>S. epidermidis</i> )
McL	120.2 [92.9-155.6]	16.1 ( <i>S. aureus</i> ); 3.3 ( <i>K. pneumoniae</i> )

PIF	>200	>1.4 ( <i>S. aureus</i> )
PIL	84.2 [74.2-95.5]	3.1 ( <i>S. aureus</i> )
PtL	>200	4.1 ( <i>K. pneumoniae</i> )
RoA	>200	>2.0 ( <i>S. aureus</i> )
SaA	>200	>1.3 ( <i>S. aureus</i> )
ThA	>200	>3.2 ( <i>S. aureus</i> )

317

318 **3.3. Clinical isolates**

319 **The three extracts selectively inhibiting bacterial growth were assayed also towards a broad array of**  
320 **relevant multi-resistant pathogens recovered from biological specimens.** In particular, **CyhA, LmA**  
321 **and PtL** were assayed against *S. aureus*, *S. epidermidis* and *K. pneumoniae* strains, respectively. Data  
322 are reported in Table 5. Remarkably, the extracts proved to be active towards all the isolates and no  
323 statistically significant differences (ANOVA followed by Dunnett's Multiple comparison) were  
324 highlighted comparing IC<sub>50</sub> values of isolates, regardless their antibiotic resistance profile (see Tables  
325 S4, S5 and S6 in the Supplementary Material), and reference strains. This is clinically relevant  
326 considering that isolates may present phenotypic and genetic heterogeneity compared to laboratory  
327 reference strains thus some differences in susceptibility may occur.

328

329 **Table 5.** IC<sub>50</sub> values of the three selected extracts towards clinical isolates. Data are reported as  
330 mean values and 95% confidence interval.

331

<b>CyhA Vs <i>S. aureus</i></b>	<b>IC<sub>50</sub> (µg/mL)</b>	<b>Antibiotic-resistance profile</b>
ATCC 25293	1.4 [0.9-1.9]	
MSSA 1	1.6 [1.3-1.9]	CM <sup>S</sup> , E <sup>S</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>S</sup> , P <sup>R</sup> , TE <sup>S</sup> , SXT <sup>S</sup>
MSSA 2	2.8 [2.1-3.9]	CM <sup>R</sup> , E <sup>R</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>S</sup> , P <sup>S</sup> , TE <sup>S</sup> , SXT <sup>S</sup>
MRSA 1 <sup>§</sup>	2.6 [1.9-3.6]	GMN <sup>S</sup> , LVX <sup>R</sup> , OX <sup>R</sup> , P <sup>R</sup> , TE <sup>S</sup> , TEC <sup>S</sup> , SXT <sup>S</sup> , VA <sup>S</sup>
MRSA 2 <sup>§</sup>	3.2 [2.4-4.4]	GMN <sup>S</sup> , LVX <sup>R</sup> , OX <sup>R</sup> , P <sup>R</sup> , TE <sup>S</sup> , TEC <sup>S</sup> , SXT <sup>S</sup> , VA <sup>S</sup>
MRSA 3 <sup>§</sup>	1.9 [1.6-2.2]	CM <sup>R</sup> , E <sup>R</sup> , GMN <sup>S</sup> , LVX <sup>R</sup> , OX <sup>R</sup> , P <sup>R</sup> , TEC <sup>S</sup> , TE <sup>S</sup> , SXT <sup>S</sup> , VA <sup>S</sup>
<b>LmA Vs <i>S. epidermidis</i></b>		
ATCC 12228	3.9 [2.5-6.1]	

ha formattato: Francese (Francia)

ha formattato: Francese (Francia)

ha formattato: Francese (Francia)

ha formattato: Francese (Francia)

MSSE 1	2.6 [1.0-6.7]	CM <sup>S</sup> , E <sup>R</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>S</sup> , TE <sup>S</sup> , SXT <sup>S</sup>
MSSE 2	4.2 [2.1-8.3]	CM <sup>S</sup> , E <sup>S</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>S</sup> , P <sup>R</sup> , TE <sup>S</sup> , SXT <sup>S</sup>
MRSE 1 <sup>§</sup>	3.0 [2.1-8.4]	CM <sup>S</sup> , E <sup>R</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>R</sup> , P <sup>R</sup> , TE <sup>S</sup> , TEC <sup>S</sup> , SXT <sup>R</sup>
MRSE 2 <sup>§</sup>	6.7 [3.9-11.5]	CM <sup>S</sup> , E <sup>S</sup> , GMN <sup>S</sup> , LVX <sup>S</sup> , OX <sup>R</sup> , TE <sup>S</sup> , SXT <sup>R</sup> , VA <sup>S</sup> , TEC <sup>S</sup>
MRSE 3 <sup>§</sup>	3.7 [1.8-7.8]	CM <sup>S</sup> , DA <sup>S</sup> , E <sup>I</sup> , GMN <sup>S</sup> , LVX <sup>R</sup> , OX <sup>R</sup> , TE <sup>S</sup> , SXT <sup>S</sup> , VA <sup>S</sup> , TEC <sup>S</sup>
<b>PtL Vs <i>K. pneumoniae</i></b>		
ATCC 9591	49.0 [42.8-56.0]	
<i>Kp 1</i>	48.7 [42.0-56.5]	AK <sup>S</sup> , AMC <sup>R</sup> , CTX <sup>R</sup> , CFZ <sup>R</sup> , CIP <sup>R</sup> , FOS <sup>S</sup> , GMN <sup>S</sup> , TZP <sup>S</sup> , SXT <sup>R</sup>
<i>Kp 2</i>	46.1 [37.5-56.6]	AK <sup>S</sup> , AMC <sup>S</sup> , CTX <sup>S</sup> , CFZ <sup>S</sup> , CIP <sup>S</sup> , FOS <sup>S</sup> , GMN <sup>S</sup> , TZP <sup>S</sup> , SXT <sup>S</sup>
<i>Kp 3</i>	45.5 [34.7-59.7]	AK <sup>S</sup> , AMC <sup>S</sup> , CTX <sup>S</sup> , CFZ <sup>S</sup> , CIP <sup>S</sup> , FOS <sup>R</sup> , GMN <sup>S</sup> , TZP <sup>S</sup> , SXT <sup>S</sup>
<i>KPC-Kp 1*</i>	53.0 [42.2-66.5]	AK <sup>R</sup> , AMC <sup>R</sup> , AMP <sup>R</sup> , CFZ <sup>R</sup> , CIP <sup>R</sup> , EPM <sup>R</sup> , GMN <sup>S</sup> , MEM <sup>R</sup> , TZP <sup>R</sup> , SXT <sup>R</sup> , TGC <sup>I</sup> , CS <sup>S</sup>
<i>KPC-Kp 2*</i>	47.3 [44.0-56.9]	AK <sup>S</sup> , AMC <sup>R</sup> , AMP <sup>R</sup> , CFZ <sup>R</sup> , CIP <sup>R</sup> , EPM <sup>R</sup> , GMN <sup>R</sup> , MEM <sup>I</sup> , TZP <sup>R</sup> , SXT <sup>R</sup> , TGC <sup>S</sup> , CS <sup>S</sup>

ha formattato: Francese (Francia)

ha formattato: Francese (Francia)

ha formattato: Francese (Francia)

332

333 AK = Amikacin; AMC = Amoxicillin/Clavulanic Acid; AMP = Ampicillin; CM = Clindamicyn; CTX = Cefotaxime;  
 334 CFZ = Ceftazidime; CIP = Ciprofloxacin; CS = Colistin; EPM = Ertapenem; E = Erythromycin; FOS = Fosfomicin;  
 335 GMN = Gentamicin; LVX = Levofloxacin; MEM = Meropenem; OX = Oxacillin; P = Penicillin; SXT =  
 336 Trimethoprim/Sulfamethoxazole; TE = Tetracycline; TEC = Teicoplanin; TZP = Piperacillin/Tazobactam, TGC =  
 337 Tigecycline; VA = Vancomycin

338

339 R = Resistant; S = Susceptible; I = Intermediate, as defined following the EUCAST guidelines

340 <sup>§</sup>*Staphylococcus* species resistant to oxacillin were declared, by convention, methicillin-resistant.

341 \*Carbapenemase-producing *K. pneumoniae*.

342

### 343 3.3 Traditional uses, bioactivities and phytochemical data of the three selected plants.

344 The effectiveness of these selected extracts validate the Sardinian plants *Cytinus hypocistis*, *Pistacia*  
 345 *terebinthus ssp. terebinthus* and *Limonium morisianum* as important source of antimicrobial  
 346 compounds. These plants might be interesting for the development of food supplements and herbal  
 347 products with antibacterial activity. Moreover, since *Limonium morisianum* is an endemic plant of  
 348 Sardinia, the obtained results might contribute also to valorize the biodiversity of the territory and the  
 349 development of local industries.

ha eliminato: information on

ha formattato: Tipo di carattere: (Predefinito) Times New Roman, Corsivo, Colore carattere: Rosso, Inglese (Stati Uniti)

ha eliminato: morisianum

ha formattato: Tipo di carattere: (Predefinito) Times New Roman, Corsivo, Colore carattere: Rosso, Inglese (Stati Uniti)

350 *Cytinus hypocistis* is a parasitic plant belonging to Cytinaceae family that grows on roots of *Cistus*  
 351 *spp.* It has been used in Sardinian traditional medicine as astringent, tonic and haemostatic (Loi et al.,

2002), to soften corns and hard skin, and to sooth epidermal inflammations (Ballero et al., 1997).  
Despite this wealth of traditional uses, its chemical composition is largely unknown. Hydrolysable  
tannins were previously identified as the main components (Magiatis et al., 2001), confirming the  
high phenolic content of **CyhA** extract observed in this study, and among them, isoterchebin,  
belonging to the ellagitannin class, was characterized (Schildknecht et al., 1985).  
Given the well-known antimicrobial properties of hydrolysable tannins (Buzzini et al., 2008) it is  
likely that these compounds might be responsible for the observed antibacterial activity of **CyhA**.  
Recently, Zucca et al. (2015) found antimicrobial activity of *C. hypocistis* but using an extraction  
procedure different from the one performed in this work. Chiocchio et al. (2018) reported also the  
anti-elastase and anti-tyrosinase activities of this plant. Moreover, antimalarial and antitumor  
properties of this plant have also been described (Fokialakis et al., 2007; Magiatis et al., 2001).  
*Pistacia terebinthus ssp. terebinthus* (Anacardiaceae), commonly known as terebinth or turpentine  
tree, is a small deciduous tree widely distributed in the Middle East and Southern Europe. In Sardinia,  
it grows only on a calcareous restricted area of east coast (Usai et al. 2006). The consumption of *P.*  
*terebinthus ssp. terebinthus* in the Mediterranean countries traced back to ancient times. For instance,  
leaves of this plant have been used for the treatment of burns and the branch resin for bronchitis and  
other respiratory afflictions, as well as for anti-inflammatory and antipyretic properties (Topcu et al.,  
2007). The mature fruits were used as a diuretic and for urinary inflammations, stomachache  
(Cakilcioglu et al., 2010), stomach ulcers (Polat et al., 2013), antiseptic, hypotensive and for headache  
(Agelet and Vallès 2003). The resin is used as a chewing gum and as food additive (Schoina et al.,  
2015). In Sardinia the decoction **has** been used to treat catarrhal cough (Bruni et a., 1997), while the  
resin as expectorant, diaphoretic, analgesic, tonic and to obtain an ointment used for the treatment of  
bladders (Atzei 2003). *P. terebinthus ssp. terebinthus* has been reported to be rich in essential oil,  
proteins, organic acids, sugars, flavonoids, tannins and resinous substances (Couladis et al., 2003;  
Marengo et al., 2018; Ozcan, 2004; Ozcan et al., 2009; Piras et al., 2017; Pulaj et a., 2016; Usai et  
al., 2006). Several studies highlighted remarkable differences in the essential oil composition of this

380 plant, attributable to geographic and climatic features (Couladis et al., 2003; Dhifi et al., 2013; Duru  
381 et al., 2003; Ismail et al., 2013; Marengo et al., 2018; Piras et al., 2017; Ulukanli et al., 2014; Pulaj  
382 et al., 2016). *P. terebinthus* ssp. *terebinthus* is reported to be active as: antibacterial, antifungal,  
383 antioxidant, cytotoxic, neuroprotective, antiinflammatory and insecticidal agent (Dhifi et al., 2013;  
384 Duru et al., 2003; Orhan et al., 2012; Ismail et al., 2013; Kavak et al., 2010; Kordali et al., 2003; Piras  
385 et al., 2017; Ulukanli et al., 2014; Pulaj et al., 2016; Topcu et al., 2007).

386 *Limonium morisianum* (Plumbaginaceae) is a dwarf frutex endemic and exclusive of calcareous  
387 mountains of Sardinia. To the best of our knowledge, no information on its use in Sardinian traditional  
388 medicine is available, since it is a very rare species. *Limonium* spp. are reported to contain several  
389 classes of active components, such as hydrolysable and condensed tannins, alkaloids, flavonoids,  
390 sterols, terpenes, saponins, coumarins, and amino acids (Blainski et al. 2013; Medini et al. 2014;  
391 Gadetskaya et al. 2015; Medini et al. 2015; de Oliveira Caleare et al. 2017). Moreover, myricetin,  
392 myricetin 3-*O*-rutinoside, myricetin-3-*O*-(6"-galloyl)- $\beta$ -D-galactopyranoside, (-)-epigallocatechin 3-*O*-  
393 gallate, tryptamine, ferulic and phloretic acids have been identified from its aerial parts (Sanna et  
394 al., 2018. **Definitely**, *L. morisianum* has been slightly studied both phytochemically and biologically.  
395 Recently, the antiviral activity has been reported against HIV-1 and Ebola viruses (Sanna et al.,  
396 **2018c**; Daino et al., 2018), as well as the ability to inhibit tyrosinase and elastase enzymes (Chiocchio  
397 et al., 2018). No information on antimicrobial and cytotoxic activities has been previously reported  
398 for any extract of this plant.

#### 399 **4. Conclusions**

400 This work reports the antimicrobial activity of some plants growing spontaneously in Sardinia (Italy).  
401 Thirty-six extracts were assayed *in vitro* towards four reference bacterial strains and evaluated for  
402 their cytotoxicity on mammalian epithelial cells.

403 The results of the biological screening, together with total phenolic and flavonoid content of the  
404 extracts, were processed through Principal Component Analysis (PCA), which highlighted the

405 positive correlation among total phenolic content and increasing antibacterial activities, and a  
406 possible involvement of flavonoids in mitigate the cytotoxicity against eukaryotic cells.

407 A significant activity was observed for thirteen extracts at non-cytotoxic concentration, and among  
408 them three emerged for their selective and potent inhibitory effect on bacterial growth; *Cytinus*  
409 *hypocistis* proved to be a broad spectrum antibacterial extract, mainly active towards *S. aureus* (IC<sub>50</sub>  
410 1.4 µg/mL), *Limonium morisianum* exhibited a potent anti-staphylococcal properties and *Pistacia*  
411 *terebinthus ssp. terebinthus* resulted the extracts with the highest SI on *K. pneumoniae*. These  
412 extracts, when tested towards isolates obtained from biological specimens and with different  
413 antibiotic-resistance profiles, confirmed their effectiveness to inhibit bacterial growth, thus validating  
414 their potential as antimicrobial agents.

#### 415 **Funding**

416 This work was supported by Fondazione Cassa di Risparmio di Imola, which contributed to the  
417 scholarship of one of the authors (M.L.).

#### 418 **Declarations of interest**

419 None

#### 420 **References**

421 Abreu AC, Paulet D, Coqueiro A, Malheiro J, Borges A, Saavedra MJ, Choi YH, Simões M., 2016.  
422 Antibiotic adjuvants from *Buxus sempervirens* to promote effective treatment of drug-resistant  
423 *Staphylococcus aureus* biofilms. RSC Advances 6, 95000-95009.  
424 <https://doi.org/10.1039/C6RA21137B>.

425 Abreu AC, Coqueiro A, Sultan AR, Lemmens N, Kim HK, Verpoorte R, Wamel WJ, Simões M, Choi  
426 YH., 2017. Looking to nature for a new concept in antimicrobial treatments: Isoflavonoids from  
427 *Cytisus striatus* as antibiotic adjuvants against MRSA. Scientific Reports. 7(1), 3777.  
428 <https://doi.org/10.1038/s41598-017-03716-7>.

429 Agelet A, Vallès J., 2003. Studies on pharmaceutical ethnobotany in the region of Pallars (Pyrenees,  
430 Catalonia, Iberian Peninsula). Part II. New or very rare uses of previously known medicinal plants. *J*  
431 *Ethnopharmacol.* 84(2–3), 211–227. [https://doi.org/10.1016/S0378-8741\(02\)00319-7](https://doi.org/10.1016/S0378-8741(02)00319-7).

432 Atzei A.D., 2003. *Le piante nella tradizione popolare della Sardegna*. Carlo Delfino editore, Sassari,  
433 Italia.

434 Ballero M, Sacchetti, G, Poli F., 1997. Plants in folk medicine in the territory of Perdasdefogu  
435 (Central Sardinia, Italy). *Allonia* 35,157-164.

436 Bartolucci F., Peruzzi L., Galasso G., Albano A., Alessandrini A., Ardenghi N.M.G., Astuti G.,  
437 Bacchetta G., Ballelli S., Banfi E., Barberis G., Bernardo L., Bouvet D., Bovio M., Cecchi L., Di  
438 Pietro R., Domina G., Fascetti S., Fenu G., Festi F., Foggi B., Gallo L., Gottschlich G., Gubellini L.,  
439 Iamónico D., Iberite M., Jiménez-Mejías P., Lattanzi E., Marchetti D., Martinetto E., Masin R.R.,  
440 Medagli P., Passalacqua N.G., Peccenini S., Pennesi R., Pierini B., Poldini L., Prosser F., Raimondo  
441 F.M., Roma-Marzio F., Rosati L., Santangelo A., Scoppola A., Scortegagna S., Selvaggi A., Selvi F.,  
442 Soldano A., Stinca A., Wagensommer R.P., Wilhalm T. & Conti F., 2018. An updated checklist of  
443 the vascular flora native to Italy. *Plant Biosystems - An International Journal Dealing with all Aspects*  
444 *of Plant Biology*, 152 (2), 179-303. <https://doi.org/10.1080/11263504.2017.1419996>.

445 Bobo-Pinilla J., Barrios de León S.B., Seguí Colomar J., Fenu G., Bacchetta G., Peñas de Giles J.,  
446 Martínez-Ortega M.M., 2016. Phylogeography of *Arenaria balearica* L. (Caryophyllaceae):  
447 evolutionary history of a disjunct endemic from the Western Mediterranean continental islands. *PeerJ*,  
448 4: e2618. <https://doi.org/10.7717/peerj.2618>.

449 Bonvicini F., Mandrone M., Antognoni F., Poli F., Gentilomi G.A., 2014. Ethanolic extracts of  
450 *Tinospora cordifolia* and *Alstonia scholaris* show antimicrobial activity towards clinical isolates of

451 methicillin-resistant and carbapenemase-producing bacteria. *Natural Product Research*, 28(18), 1438-  
452 1445. <https://doi.org/10.1080/14786419.2014.909421>.

453 Bonvicini F., Antognoni F, Mandrone M., Protti M., Mercolini L., Lianza M., Gentilomi G. A., Poli  
454 F., 2017. Phytochemical analysis and antibacterial activity towards methicillin-resistant  
455 *Staphylococcus aureus* of leaf extracts from *Argania spinosa* (L.) Skeels. *Plant Biosyst.* 151 (4), 649-  
456 656. <https://doi.org/10.1080/11263504.2016.1190418>.

457 Bonvicini F., Lianza M., Mandrone M., Poli F., Gentilomi G.A., Antognoni F., 2018. *Hemidesmus*  
458 *indicus* (L.) R. Br. extract inhibits the early step of herpes simplex type 1 and type 2 replication. *New*  
459 *Microbiologica*, 41(3), 187-194.

460 Blainski A, Lopes GC, De Mello JCP., 2013. Application and analysis of the folin ciocalteu method  
461 for the determination of the total phenolic content from *Limonium brasiliense* L. *Molecules.* 18,  
462 6852–6865. <https://doi.org/10.3390/molecules18066852>.

463 Bruni A, Ballero M, Poli F., 1997. Quantitative ethnopharmacological study of the Campidano Valley  
464 and Urzulei district, Sardinia, Italy. *J. Ethnopharmacol* 57, 97-124. [https://doi.org/10.1016/S0378-](https://doi.org/10.1016/S0378-741(97)00055-X)  
465 [8741\(97\)00055-X](https://doi.org/10.1016/S0378-741(97)00055-X).

466 Buzzini P, Arapitsas P, Goretti M, Turchetti B, Pinelli P, Ieri F, Romani A., 2008. Antimicrobial and  
467 antiviral activity of hydrolysable tannins. *Mini-Rev Med Chem.* 8(12), 1179–1187.  
468 <https://doi.org/10.2174/138955708786140990>.

469 Cagno V., Sgorbini B., Sanna C., Cagliero C., Ballero M., Donalisio M., Bicchi C., Lembo D.,  
470 Rubiolo P., 2017. In vitro anti-herpes simplex virus-2 activity of *Salvia desoleana* Atzei & V. Picci  
471 essential oil. *PLoS ONE*, 12(2), e0172322. <https://doi.org/10.1371/journal.pone.0172322>.

472 Cakilcioglu U, Turkoglu I., 2010. An ethnobotanical survey of medicinal plants in Sivrice (Elazığ-  
473 Turkey). *J. Ethnopharmacol* 132(1), 165–175. <https://doi.org/10.1016/j.jep.2010.08.017>.



474 Chen P., Li C., Li X., Li J., Chu R., Wang H., 2014. Higher dietary folate intake reduces the breast  
475 cancer risk: a systematic review and meta-analysis. *Br. J. Cancer.* 110, 2327-2338.  
476 <https://doi.org/10.1038/bjc.2014.155>.

477 Chiocchio I., Mandrone M., Sanna C., Maxia A., Tacchini M., Poli F., 2018. Screening of a hundred  
478 plant extracts as tyrosinase and elastase inhibitors, two enzymatic targets of cosmetic interest. *Ind.*  
479 *Crops. Prod.* 122, 498-505. <https://doi.org/10.1016/j.indcrop.2018.06.029>.

480 Coqueiro, A., Choi, Y. H., Verpoorte, R., Gupta, K. B., De Mieri, M., Hamburger, M., Bolzani, V.  
481 D.S., 2016. Antistaphylococcal prenylated acylphoroglucinol and xanthenes from *Kielmeyera*  
482 *variabilis*. *J. Nat. Prod.* 79, 470-476. <https://doi.org/10.1021/acs.jnatprod.5b00858>.

483 Cos P., Vlietinck A.J., Berghe D.V., Maes L., 2006. Anti-infective potential of natural products: How  
484 to develop a stronger in vitro 'proof-of-concept'. *J. Ethnopharmacol.* 106, 290-302.  
485 <https://doi.org/10.1016/j.jep.2006.04.003>.

486 Couladis M., Özcan M., Tzakou O., Akgu A., 2003. Comparative essential oil composition of various  
487 parts of the turpentine tree (*Pistacia terebinthus* L) growing wild in Turkey. *Sci. Food Agric.* 83,136–  
488 138. <https://doi.org/10.1002/jsfa.1295>.

489 Cragg, G. M, Newman, D.J., 2013. Natural products: a continuing source of novel drug leads.  
490 *Biochim. Biophys. Acta.*1830(6), 3670–3695. <https://doi.org/10.1016/j.bbagen.2013.02.008>.

491 Daino G.L., Frau A., Sanna C., Rigano D., Distinto S., Madau V., Esposito F., Fanunza E., Bianco  
492 G., Tagliatalata Scafati O., Zinzula L., Maccioni E., Corona A., Tramontano E., 2018. Identification  
493 of Myricetin as Ebolavirus VP35-dsRNA interaction inhibitor through a novel fluorescence-based  
494 assay. *Biochemistry*, 57(44), 6367-6378. <https://doi.org/10.1021/acs.biochem.8b00892>.

495 de Oliveira Caleare A, Hensel A, Mello JCP, Pinha AB, Panizzon GP, Lechtenberg M, Petereit F,  
496 Nakamura CV., 2017. Flavan-3-ols and proanthocyanidins from *Limonium brasiliense* inhibit the

497 adhesion of *Porphyromonas gingivalis* to epithelial host cells by interaction with gingipains.  
498 *Fitoterapia*. 118, 87–93. <https://doi.org/10.1016/j.fitote.2017.03.002>.

499 Dettori C.A., Loi M.C., Brullo S., Fraga Arguimbau P., Tamburini E., Bacchetta G., 2016. The  
500 genetic diversity and structure of the *Ferula communis* L. complex (Apiaceae) in the Tyrrhenian area.  
501 *Flora*, 223, 138–146. <https://doi.org/10.1016/j.flora.2016.05.007>.

502 Dhifi W., Mnif W., Ouerhani B. & Ghrissi K., 2012. Chemical Composition and Antibacterial  
503 Activity of Essential Oil from the Seeds of *Pistacia terebinthus* grown in Tunisia. *J. Essent. Oil Bear.*  
504 *Plants.*, 15:4, 582-58. <https://doi.org/10.1080/0972060X.2012.10644092>.

505 **Dikpınar T., Süzgeç-Selçuk S., Çelik B.Ö., Uruşak E.A., 2018. Antimicrobial activity of rhizomes of**  
506 ***Ferulago trachycarpa* Boiss. and bioguided isolation of active coumarin constituents. *Ind. Crop.***  
507 ***Prod.* 123, 762-767. <https://doi.org/10.1016/j.indcrop.2018.06.072>**

508 Duru ME, Cakir A, Kordali S, Zengin H, Harmandar M, Izumi S, Hirata T., 2003. Chemical  
509 composition and antifungal properties of essential oils of three *Pistacia* species. *Fitoterapia*. 74(1-2),  
510 170-176. [https://doi.org/10.1016/S0367-326X\(02\)00318-0](https://doi.org/10.1016/S0367-326X(02)00318-0).

511 Fois M, Fenu G, Cañadas EM, Bacchetta G., 2017. Disentangling the influence of environmental and  
512 anthropogenic factors on the distribution of endemic vascular plants in Sardinia. *PLoS ONE* 12(8),  
513 e0182539. <https://doi.org/10.1371/journal.pone.0182539>.

514 Fokialakis N, Kalpoutzakis E, Tekwani BL, Khan SI, Kobaisy M, Skaltsounis AL, Duke SO., 2007.  
515 Evaluation of the antimalarial and antileishmanial activity of plants from the Greek island of Crete.  
516 *J. Nat. Med.* 61(1), 38–45. <https://doi.org/10.1007/s11418-006-0013-y>.

517 Fung T.T., Chiuve S.E, Willett W.C., Hankinson S.E., Hu F.B., Holmes M.D., 2013. Intake of  
518 specific fruits and vegetables in relation to risk of estrogen receptor-negative breast cancer among

519 postmenopausal women. *Breast Cancer Res. Treat.* 138, 925-930. [https://doi.org/10.1007/s10549-](https://doi.org/10.1007/s10549-013-2484-3)  
520 013-2484-3.

521 Gadetskaya A V., Tarawneh AH, Zhusupova GE, Gemejiyeva NG, Cantrell CL, Cutler SJ, Ross SA.  
522 2015. Sulfated phenolic compounds from *Limonium caspium*: Isolation, structural elucidation, and  
523 biological evaluation. *Fitoterapia.* 104,80–85. <https://doi.org/10.1016/j.fitote.2015.05.017>.

524 Gomes F., Martins N., Barros L., Rodrigues M.E., Oliveira M.B.P.P., Henriques M., Ferreira I.C.F.R.,  
525 2017. Plant phenolic extracts as an effective strategy to control *Staphylococcus aureus*, the dairy  
526 industry pathogen. *Ind. Crop. Prod.* 112, 515-520. <https://doi.org/10.1016/j.indcrop.2017.12.027>

527 Hosseinzadeh, H., & Nassiri-Asl, M., 2014. Review of the protective effects of rutin on the metabolic  
528 function as an important dietary flavonoid. *J. Endocrinol. Invest.* 37, 783-788.  
529 <https://doi.org/10.1007/s40618-014-0096-3>.

530 Ismail A., Lamia H., Mohsen H., Samia G., Bassem J., 2013. Chemical composition and antifungal  
531 activity of three Anacardiaceae species grown in Tunisia. *Sci. Int.* 1(5),148–154.  
532 <https://doi.org/10.5567/sciintl.2013.148.154>.

533 Jahangir M., Kim H.K., Choi Y.H., Verpoorte R., 2008. Metabolomic response of *Brassica rapa*  
534 submitted to preharvest bacterial contamination. *Food Chem.* 107, 362-368.  
535 <https://doi.org/10.1016/j.foodchem.2007.08.034>.

536 Kavak D.D., Altıok E., Bayraktar O., Ülkü S., 2010. *Pistacia terebinthus* extract: As a potential  
537 antioxidant, antimicrobial and possible  $\beta$ -glucuronidase inhibitor. *J. Mol. Catal. B-Enzym.* 64(3-4),  
538 167-171. <https://doi.org/10.1016/j.molcatb.2010.01.029>.

539 Kim, H.K., Choi, Y.H., & Verpoorte, R., 2010. NMR-based metabolomic analysis of plants. *Nat.*  
540 *Protoc.* 5(3), 536. <https://doi.org/10.1038/nprot.2009.237>.

ha formattato: Italiano (Italia)

ha formattato: Italiano (Italia)

ha formattato: Italiano (Italia)

Codice campo modificato

541 Kordali S, Cakir A, Zengin H, Duru ME., 2003. Antifungal activities of the leaves of three *Pistacia*  
542 species grown in Turkey. *Fitoterapia*, 74(1-2),164-7. [https://doi.org/10.1016/S0367-326X\(02\)00320-](https://doi.org/10.1016/S0367-326X(02)00320-9)  
543 9.

ha formattato: Francese (Francia)

544 Loi M.C., Frailis L., Maxia A., 2002. Medicinal plants commonly used in the Gesturi territory  
545 (Central-Southern Sardinia). *Atti Soc. Tosc. Sci. Nat. Mem. Ser. B.* 109, 167–76.

546 Magiatis P, Pratsinis H, Kalpoutzakis E, Konstantinidou A, Davaris P, Skaltsounis AL., 2001.  
547 Hydrolyzable tannins, the active constituents of three Greek *Cytinus* taxa against several tumor cell  
548 lines. *Biol. Pharm. Bull.* 24(6), 707–709. <https://doi.org/10.1248/bpb.24.707>.

549 Mahady G, Lawal LO, Raut N, Wick SM., 2018. Natural products and traditional medicines for the  
550 treatment of multidrug resistant bacteria. *Medical Research Archives* 6(1).  
551 <https://doi.org/10.18103/mra.v6i1.1639>.

552 Mandrone M., Lorenzi B., Venditti A., Guarcini L., Bianco A., Sanna C., Ballero M., Poli F.,  
553 Antognoni F., 2015. Antioxidant and anti-collagenase activity of *Hypericum hircinum* L. *Ind. Crop.*  
554 *Prod.* 76, 402-408. <https://doi.org/10.1371/journal.pone.0195168>.

Codice campo modificato

555 Mandrone M., Scognamiglio M., Fiorentino A., Sanna C., Cornioli L., Antognoni F., Bonvicini F.,  
556 Poli F., 2017 Phytochemical profile and  $\alpha$ -glucosidase inhibitory activity of Sardinian *Hypericum*  
557 *scruglii* and *Hypericum hircinum*. *Fitoterapia*, 120, 184-193.  
558 <https://doi.org/10.1016/j.fitote.2017.06.020>.

559 Mandrone, M., Coqueiro, A., Poli, F., Antognoni, F., Choi, Y.H., 2018. Identification of a  
560 collagenase-inhibiting flavonoid from *Alchemilla vulgaris* using NMR-based metabolomics. *Planta*  
561 *Med.*, 84(12/13), 941-946. <https://doi.org/10.1055/a-0630-2079>.

562 Marengo A., Maxia A., Sanna C., Berteà C.M., Bicchi C., Ballero M., Cagliari C, Rubiolo P., 2017  
563 - Characterization of four wild edible *Carduus* species from the Mediterranean region via

564 phytochemical and biomolecular analyses. Food Res. Int., 100. 822-831.  
565 <https://doi.org/10.1016/j.foodres.2017.07.071>.

566 Marengo A, Piras A, Falconieri D, Porcedda S, Caboni P, Cortis P, Foddìs C, Loi C, Gonçalves MJ,  
567 Salgueiro L, Maxia A., 2018. Chemical and biomolecular analyses to discriminate three taxa of  
568 *Pistacia* genus from Sardinia Island (Italy) and their antifungal activity. Nat. Prod. Res. [32\(23\): 2766-](https://doi.org/10.1080/14786419.2017.1378211)  
569 [2774](https://doi.org/10.1080/14786419.2017.1378211), <https://doi.org/10.1080/14786419.2017.1378211>.

570 Marignani M., Bruschi D., Astiaso Garcia D., Frondoni R., Carli E., Pinna M.S., Cumo F.,  
571 Gugliermetti F., Saatkamp A., Doxa A., Queller E.M., Chaieb M., Bou Dagher-Kharrat M., El Zein  
572 R., El Jeitani S., Khater C., Mansour S., Al-Shami A., Harik G., Alameddine I., El-Fadel M., Blasi  
573 C., 2017. Identification and prioritization of areas with high environmental risk in Mediterranean  
574 coastal areas: A flexible approach. Sci. Total Environ. 590-591,566-578.  
575 <https://doi.org/10.1016/j.scitotenv.2017.02.221>.

576 Maxia A., Sanna C., Piras A., Porcedda S., Falconieri D., Gonçalves MJ., Cavaleiro C., Salgueiro L.,  
577 2015 - Chemical composition and biological activity of *Tanacetum audibertii* (Req.) DC.  
578 (Asteraceae), an endemic species of Sardinia Island, Italy. Ind. Crop. Prod. [65](https://doi.org/10.1016/j.indcrop.2014.10.039), 472-476.  
579 <https://doi.org/10.1016/j.indcrop.2014.10.039>.

580 May L., Klein E.Y., Rothman R. E., Laxminrayan R., 2014. Trends in Antibiotic Resistance in  
581 Coagulase-Negative Staphylococci in the United States, 1999 to 2012. Antimicrob. Agents  
582 Chemother. 58(3), 1404-1409. <https://doi.org/10.1128/AAC.01908-13>.

583 Medail F. & Quezel P., 1999. Biodiversity hotspots in the Mediterranean Basin: setting global  
584 conservation priorities. Conserv. Biol., 13, 1510-1513.

ha eliminato: 20, 1-9

586 Médail, F. & Quézel, P., 1997. Hot-spots analysis for conservation of plant biodiversity in the  
587 Mediterranean Basin. *Annals of the Missouri Botanical Garden.* 84, 112-127.  
588 <https://doi.org/10.2307/2399957>.

589 Medini F, Bourgou S, Lalancette K, Snoussi M, Mkadimi K, Coté I, Abdelly C, Legault J, Ksouri  
590 R., 2015. Phytochemical analysis, antioxidant, anti-inflammatory, and anticancer activities of the  
591 halophyte *Limonium densiflorum* extracts on human cell lines and murine macrophages. *S. Afr. J.*  
592 *Bot.* 99, 158–164. <https://doi.org/10.1016/j.sajb.2015.04.007>.

593 Medini F, Fellah H, Ksouri R, Abdelly C., 2014. Total phenolic, flavonoid and tannin contents and  
594 antioxidant and antimicrobial activities of organic extracts of shoots of the plant *Limonium*  
595 *delicatulum*. *J. Taibah Univ. Sci.* 8,216–224. <https://doi.org/10.1016/j.jtusci.2014.01.003>.

ha formattato: Francese (Francia)

596 Moellering R.C., 2012. MRSA: the first half century. *J. Antimicrob. Chemother.* 67, 4-11.  
597 <https://doi.org/10.1093/jac/dkr437>.

598 Nordmann P., Naas T., Poirel L., 2011. Global spread of carbapenemae-producing  
599 Enterobacteriaceae. *Emerg. Infect. Dis.* 17(10), 1791-1798. <https://doi.org/10.3201/eid1710.110655>.

ha formattato: Francese (Francia)

600 Orhan I.E., Sezer Senol F., Rifat Gulpinar A., Sekeroglu N., Kartal M., Sener B., 2012.  
601 Neuroprotective potential of some terebinth coffee brands and the unprocessed fruits of *Pistacia*  
602 *terebinthus* L. and their fatty and essential oil analyses. *Food Chem.* 130, 882–888.  
603 <https://doi.org/10.1016/j.foodchem.2011.07.119>.

604 Ornano L., Venditti A., Donno Y., Sanna C., Ballero M., Bianco A., 2016 - Phytochemical analysis  
605 of non-volatile fraction of *Artemisia caerulescens subsp. densiflora* (Viv.) (Asteraceae), An endemic  
606 species of La Maddalena Archipelago (Sardinia-Italy). *Nat. Prod. Res.* 30, 920-925.  
607 <https://doi.org/10.1080/14786419.2015.1079189>.

608 Ozcan, M., 2004. Characteristics of fruit and oil of terebinth (*Pistacia terebinthus* L.) growing wild  
609 in Turkey. J. Sci. Food Agric. 84, 517–520. <https://doi.org/10.1002/jsfa.1632>.

610 Özcan, M. M., Tzakou, O., Couladis, M., 2009. Essential oil composition of the turpentine tree  
611 (*Pistacia terebinthus* L.) fruits growing wild in Turkey. Food Chem. 114, 282–285.  
612 <https://doi.org/10.1016/j.foodchem.2008.08.094>.

613 Piras A, Marzouki H, Maxia A, Marengo A, Porcedda S, Falconieri D, Gonçalves MJ, Cavaleiro C,  
614 Salgueiro L., 2017. Chemical characterisation and biological activity of leaf essential oils obtained  
615 from *Pistacia terebinthus* growing wild in Tunisia and Sardinia Island. Nat. Prod. Res. 31(22), 2684-  
616 2689. <https://doi.org/10.1080/14786419.2017.1289204>.

617 Polat R, Cakilcioglu U, Satil F., 2013. Traditional uses of medicinal plants in Solhan (Bingöl -  
618 Turkey). J. Ethnopharmacol. 48(3), 951–63. <https://doi.org/10.1016/j.jep.2013.05.050>.

619 Pulaj B, Mustafa B, Nelson K, Quave CL, Hajdari A., 2016. Chemical composition and in vitro  
620 antibacterial activity of *Pistacia terebinthus* essential oils derived from wild populations in Kosovo.  
621 BMC Complement. Altern. Med. 16, 147–155. <https://doi.org/10.1186/s12906-016-1135-8>.

622 Rolo J., de Lencastre H., Miragaia M., 2012. Strategies of adaptation of *Staphylococcus epidermidis*  
623 to hospital and community: amplification and diversification of SCCmec. J. Antimicrob. Chemother.  
624 67, 1333–1341. <https://doi.org/10.1093/jac/dks068>.

625 Sanna C, Rigano D, Corona A, Piano D, Formisano C, Farci D, Franzini G, Ballero M, Chianese G,  
626 Tramontano E, Tagliatela-Scafati O, Esposito F., 2018c - Dual HIV-1 reverse transcriptase and  
627 integrase inhibitors from *Limonium morisianum* Arrigoni, an endemic species of Sardinia (Italy). Nat.  
628 Prod. Res. 4, 1-6. <https://doi.org/10.1080/14786419.2018.1434649>.

629 Sanna C., Rigano D., Cortis P., Corona A., Ballero M., Parolin C., Del Vecchio C., Chianese G.,  
630 Saccon E., Formisano C., Tramontano E., Esposito F., 2018a - *Onopordum illyricum* L., a

ha formattato: Francese (Francia)

ha formattato: Francese (Francia)

631 Mediterranean plant, as a source of anti HIV-1 compounds. *Plant Biosyst.*152(6), 1274-1281.  
632 <https://doi.org/10.1080/11263504.2018.1439118>.

ha eliminato: ).

633 Sanna C, Scognamiglio M, Fiorentino A, Corona A, Graziani V, Caredda A, Cortis P, Montisci M,  
634 Ceresola ER, Canducci F, Poli F., Tramontano E., Esposito F., 2018b. Prenylated phloroglucinols  
635 from *Hypericum scruglii*, an endemic species of Sardinia (Italy), as new dual HIV-1 inhibitors  
636 effective on HIV-1 replication. *PLoS One.* 13(3):e0195168.  
637 <https://doi.org/10.1371/journal.pone.0195168>.

638 Scavo A., Pandino G., Restuccia C., Parafati L., Cirvilleri G., Mauromicale G., 2019. Antimicrobial  
639 activity of cultivated cardoon (*Cynara cardunculus* L. var. *altilis* DC.) leaf extracts against bacterial  
640 species of agricultural and food interest. *Ind. Crop. Prod.* 129, 206-211.  
641 <https://doi.org/10.1016/j.indcrop.2018.12.005>

642 Schildknecht H., Herb R., Kunzelmann P., 1985. Die Chemie der Schmarotzerblumen, II.  
643 Isoterchebin: Struktur des gelben Ellagitannin-Farbstoffes aus *Cytinus hypocistis* (Rafflesiaceae).  
644 *Liebigs Ann Chem*, (7),1448–1456.

ha formattato: Francese (Francia)

645 Schoina V., Terpou A., Gialleli A-I, Koutinas A, Kanellaki M, Bosnea L., 2015. Use of *Pistacia*  
646 *terebinthus* resins immobilization support for *Lactobacillus casei* cells and application in selected  
647 dairy products. *J. Food Sci. Technol.* 52, 5700–5708. <https://doi.org/10.1007/s13197-014-1627-9>.

ha formattato: Inglese (Stati Uniti)

648 Snene A., El Mokni R., Jmii H., Jlassi I., Jaïdane H., Falconieri D., Piras A., Dhaouadi H., Porcedda  
649 S., Hammami S., 2017. In vitro antimicrobial, antioxidant and antiviral activities of the essential oil  
650 and various extracts of wild (*Daucus virgatus* (Poir.) Maire) from Tunisia. *Ind. Crop. Prod.* 109, 109-  
651 115. <http://dx.doi.org/10.1016/j.indcrop.2017.08.015>

652 Toledo E., Salas-Salvadó J., Donat-Vargas C., Buil-Cosiales P., Estruch R., Ros E., Corella D., Fitó  
653 M., Hu F.B., Arós F., Gómez-Gracia E., Romaguera D., Ortega- Calvo M., Serra-Majem L., Pintó



655 X., Schröder H., Basora J., Sorlí J.V., Bulló M., Serra-Mir M., Martínez-González M.A., 2015.  
656 Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the  
657 PREDIMED trial: a randomized clinical trial. *JAMA Intern. Med.* 175,1752-1760.  
658 <https://doi.org/10.1001/jamainternmed.2015.4838>.

659 Topcu G, Ay M, Bilici A, Sarikuerkcue C, Oezturk M, Ulubelen A., 2007. A new flavone from  
660 antioxidant extracts of *Pistacia terebinthus*. *Food Chem.* 103(3), 816-822.  
661 <https://doi.org/10.1016/j.foodchem.2006.09.028>.

662 Ulukanli Z, Karaborklu S, Ozturk B, Çenet M, Balcilar M., 2014. Chemical composition, antibacterial  
663 and insecticidal activities of the essential oil from the *Pistacia terebinthus* L. Spp. Palaestina (Boiss.)  
664 (Anacardiaceae). *J. Food Process. Preserv.* 38(3), 815-822. <https://doi.org/10.1111/jfpp.12035>.

665 Usai M, Pintore G, Chessa M, Tirillini B., 2006. Essential oil composition of different aerial parts of  
666 *Pistacia terebinthus* L. growing wild in Sardinia. *J. Essent. Oil Res.* 18, 383-385.  
667 <https://doi.org/10.1080/10412905.2006.9699121>.

668 Venditti A, Lattanzi C, Ornano L, Maggi F, Sanna C, Ballero M, Alvino A, Serafini M, Bianco A.,  
669 2016 - A new glucosidic phthalide from *Helichrysum microphyllum* subsp. *tyrrhenicum* from La  
670 Maddalena Island (Sardinia, Italy). *Nat. Prod. Res.* 30(7), 789-795.  
671 <https://doi.org/10.1080/14786419.2015.1067619>.

672 Venditti A, Maggi F, Quassinti L, Bramucci M, Lupidi G, Ornano L, Ballero M, Sanna C, Bruno M,  
673 Rosselli S, Bianco A., 2018. Bioactive Constituents of *Juniperus turbinata* Gussone from La  
674 Maddalena Archipelago. *Chem. Biodivers.* 15, e1800148. <https://doi.org/10.1002/cbdv.201800148>.

675 Venditti A., Sanna C., Lorenzetti L.M., Ballero M., Bianco A., 2017 - New coumarinyl ethers in  
676 *Daphne oleoides* Schreb. collected from Sardinia Island. *Chem. Biodivers.*, 14 (6), e1700072.  
677 <https://doi.org/10.1002/cbdv.201700072>.

ha formattato: Italiano (Italia)


ha formattato: Inglese (Stati Uniti)

Codice campo modificato

- 678 Verpoorte, R., Choi, Y.H., & Kim, H.K., 2007. NMR-based metabolomics at work in phytochemistry.  
679 *Phytochem. Reviews*, 6(1), 3-14. <https://doi.org/10.1007/s11101-006-9031-3>.
- 680 Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, van der Heijden R, Voshol PJ,  
681 Havekes LM, Verpoorte R, van der Greef J., 2005. Metabolomics in the context of systems biology:  
682 bridging traditional Chinese medicine and molecular pharmacology. *Phytother. Res.* 19, 173–182.  
683 DOI: 10.1002/ptr.1624
- 684 World Health Organization. 2014. Antimicrobial resistance: global report on surveillance.
- 685 Zucca P, Pintus M, Manzo G, Nieddu M, Steri D, Rinaldi AC., 2015. Antimicrobial, antioxidant and  
686 anti-tyrosinase properties of extracts of the Mediterranean parasitic plant *Cytinus hypocistis*. *BMC*  
687 *Res. Notes.* 8, 562. <https://doi.org/10.1186/s13104-015-1546-5>.


ha eliminato :

Fig. 1



**Fig 2.**

**A**



**B**

